Bain Capital, LP is one of the world’s leading private multi-asset alternative investment firms with over $105 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].

Media Contacts

Featured Article

Private Equity // January 15, 2019

Brillio Announces Investment by Bain Capital Private Equity

SANTA CLARA, CA, January 15 2019 - Brillio, a global digital technology consulting and solutions company, today announced the signing of a definitive agreement for Bain Capital Private Equity to acquire a majority stake in the company to further scale its digital transformation offerings. Brillio will continue to be led by the current management team, headed by Chief Executive Officer Raj...

  • 1.3.19
    Double Impact

    Bain Capital Double Impact Acquires HealthDrive - National Leader for Onsite Physician Services to Long-Term Care Residents

    WELLESLEY, MA. and BOSTON, January 3, 2019 - Bain Capital Double Impact, the impact investing business of Bain Capital, today announced the acquisition of HealthDrive, a specialty provider of on-site dentistry, optometry, podiatry, and audiology to residents in long-term care, skilled nursing, and assisted living facilities. The partnership will allow HealthDrive to expand its services and create...

  • 12.19.18
    Life Sciences

    Annexon Biosciences Closes $75 Million Financing

    SOUTH SAN FRANCISCO, CA, December 19, 2018 - Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing. The financing was led by new investor Bain Capital Life Sciences, with participation by Surveyor Capital (a Citadel...

  • 12.19.18

    Bain Capital Specialty Finance, Inc. Announces Quarterly Dividend

    BOSTON, December 19, 2018 – Bain Capital Specialty Finance, Inc. (NYSE: BCSF) or “BCSF” today announced that its Board of Directors has declared a quarterly dividend of $0.41 per share of common stock. The dividend will be payable on January 14, 2019 to stockholders of record as of the close of business on December 31, 2018.“We are pleased to announce our first declared dividend as a...

  • 12.10.18
    Private Equity

    Bain-backed Italmatch Chemicals buys BWA Water Additives

    GENOA, December 10, 2018 – Italmatch Chemicals, a leading global specialty chemical group focused on the production and marketing of performance additives for water & process treatment, oil & gas, industrial lubricants and plastics, today announces that it has signed an agreement to acquire BWA Water Additives, a leading global provider of sustainable water management solutions for the...

  • 11.29.18
    Life Sciences

    ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

    SAN DIEGO, November 29, 2018 – ViaCyte, Inc., a privately-held clinical stage regenerative medicine company, today announced an $80 million Series D financing led by Bain Capital Life Sciences and joined by TPG and RA Capital Management, as well as existing investor, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further...

  • 11.28.18

    Bain Capital Specialty Finance, Inc.’s Board of Directors Recommends Proposal for Shareholder Vote to Reduce Asset Coverage Requirement

    BOSTON, November 28, 2018 – Bain Capital Specialty Finance, Inc. (NYSE: BCSF) or “the Company” or “BCSF” today announced that its Board of Directors (the “Board”) has recommended that shareholders approve a proposal to reduce the Company’s required minimum asset coverage requirements applicable to Business Development Companies under the Investment Company Act of 1940, as amended...

  • 11.20.18

    KKR and Bain Capital Establish $20 Million TRU Financial Assistance Fund

    NEW YORK/BOSTON, November 20, 2018 - KKR & Co. Inc. (NYSE:KKR) and Bain Capital, L.P. today announced the establishment of the TRU Financial Assistance Fund (the “Fund”) to allocate and distribute funds to certain former Toys “R” Us employees in the U.S. business who lost their jobs as a result of the severe disruption in the retail industry and the liquidation of the business. KKR...

  • 11.14.18

    Bain Capital Specialty Finance, Inc. Prices Public Offering

    BOSTON, November 14, 2018 — Bain Capital Specialty Finance, Inc. (“BCSF”), a business development company managed by anaffiliate of Bain Capital, LP, today announced that it priced its initial public offering of 7,500,000 shares of its common stock at $20.25 per share. Shares of common stock of BCSF are expected to begin trading on the New York Stock Exchange on November 15, 2018 under the...

  • 11.7.18

    Bain Capital Specialty Finance, Inc. Announces Planned Initial Public Offering

    BOSTON, November 7, 2018 - Bain Capital Specialty Finance, Inc. (“BCSF”), a business development company managed by an affiliate of Bain Capital, LP, today announced that it plans to make an initial public offering of 7,500,000 shares of its common stock. BCSF has been approved to list its common stock on the New York Stock Exchange under the symbol “BCSF.” The underwriters are expected...

  • 10.23.18
    Private Equity
    Life Sciences

    Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company

    BOSTON and NEW YORK, October 23, 2018 – Bain Capital, LP and Pfizer Inc. (NYSE: PFE) today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three...

Latest @BainCapital tweets